The sustained increase of cardiovascular risk following COPD exacerbations: meta-analyses of the EXACOS-CV studies
Risk of severe cardiovascular events is sustainably increased following an exacerbation of COPD, even early and moderate ones. Cardiopulmonary risk reduction should be a global core target of COPD management.
Authors
- Kirsty Rhodes (ORCID: https://orcid.org/0000-0002-8568-4979)
- Aaro Salosensaari (ORCID: https://orcid.org/0000-0001-6698-6093)
- Clémentine Nordon (ORCID: https://orcid.org/0000-0001-9441-9723)
- Jonathan Marshall (ORCID: https://orcid.org/0000-0001-5296-6075)
- Hana Müllerová (ORCID: https://orcid.org/0000-0002-0949-0101)
- Ana C. Santos (ORCID: https://orcid.org/0000-0001-7436-7954)
- Claus Franz Vogelmeier (ORCID: https://orcid.org/0000-0002-9798-2527)
- Sami O. Simons (ORCID: https://orcid.org/0000-0002-4296-5076)
- Muriel Lobier (ORCID: https://orcid.org/0000-0003-1174-1288)
- Michael Pollack (ORCID: https://orcid.org/0000-0001-7351-3059)
- Fabian Hoti (ORCID: https://orcid.org/0000-0002-7464-3549)
- Camilla Bengtsson (ORCID: https://orcid.org/0000-0003-0157-3081)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Maastricht University Medical Centre (NL)
- IQVIA (United Kingdom) (GB)
- Maastricht University (NL)
- IQM (Finland) (FI)
- AstraZeneca (Switzerland) (CH)
- German Center for Lung Research (DE)
- AstraZeneca (Italy) (IT)
- Immune Therapy Holdings (Sweden) (SE)
- Escola Secundária Quinta do Marquês (PT)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1183/23120541.01091-2024
- Citations
- 13
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- AstraZeneca